A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
(TRITON2 Trial)
Recruiting in Palo Alto (17 mi)
+148 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: pharmaand GmbH
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
Research Team
Eligibility Criteria
Inclusion Criteria
Be 18 years old at the time the informed consent form is signed
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
See 2 more
Treatment Details
Interventions
- Rucaparib (PARP Inhibitor)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: RucaparibExperimental Treatment1 Intervention
Oral rucaparib (monotherapy)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Premier Urology Associates dba/AdvanceMed ResearchLawrenceville, NJ
SCRI - Tennessee OncologyNashville, TN
Texas Oncology Medical City DallasDallas, TX
UT Health Science CenterHouston, TX
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
pharmaand GmbH
Lead Sponsor
Trials
22
Patients Recruited
4,300+
Clovis Oncology, Inc.
Lead Sponsor
Trials
65
Patients Recruited
11,100+
zr Pharma & GmbH
Lead Sponsor
Trials
21
Patients Recruited
4,200+
Foundation Medicine
Industry Sponsor
Trials
37
Patients Recruited
17,600+